Phenotypes associated with this allele

• Allele Symbol: Efnb2^tm2And
• Allele Name: targeted mutation 2, David J Anderson
• Allele ID: MGI:2176538
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Efnb2^tm1And/Efnb2^tm2And Tg(Tek-cre)12Flv/0	involves: 129S7/SvEvBrd * C57BL/6	MGI:2176622
cn2	Efnb2^tm2And/Efnb2^tm2And Tg(CAG-cre/Esr1*)1Egwa/0	involves: 129S7/SvEvBrd * C57BL/6 * DBA/2	MGI:4430085

Genotype
MGI:2176622

cn1

• Allelic Composition: Efnb2^tm1And/Efnb2^tm2And; Tg(Tek-cre)12Flv/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:74909 )

• mutant embryos die by E11

cardiovascular system

abnormal intersomitic vessel morphology ( J:74909 )

• embryos exhibit an arrest in intersomitic vessel angiogenesis at the primary plexus stage; the vessels appear fused dorsally with little or no branching

abnormal vascular development ( J:74909 )

• vasculature is disorganized and less developed

abnormal angiogenesis ( J:74909 )

• E9.5 mutants exhibit a failure of anterior cardinal vein assembly

• the capillary bed of the head appears dilated and arrested at the primary plexus stage

• embryos exhibit an arrest in intersomitic vessel angiogenesis at the primary plexus stage; the vessels appear fused dorsally with little or no branching

abnormal developmental vascular remodeling ( J:74909 )

• E9.5 mutants exhibit a failure of anterior cardinal vein assembly and remodeling

abnormal vitelline vasculature morphology ( J:74909 )

• yolk sac is a homogeneous capillary bed at E9.5, indicating arrest of artery and vein development at the primary plexus stage

absent myocardial trabeculae ( J:74909 )

• little or no myocardial trabecular extensions by E9

abnormal heart looping ( J:74909 )

• heart looping defects

enlarged heart ( J:74909 )

• hearts are swollen at E9.5

embryo

abnormal vitelline vasculature morphology ( J:74909 )

• yolk sac is a homogeneous capillary bed at E9.5, indicating arrest of artery and vein development at the primary plexus stage

embryonic growth arrest ( J:74909 )

• embryos are developmentally less advanced at E9.5

decreased embryo size ( J:74909 )

• evident at E10

growth/size/body

enlarged heart ( J:74909 )

• hearts are swollen at E9.5

decreased embryo size ( J:74909 )

• evident at E10

muscle

absent myocardial trabeculae ( J:74909 )

• little or no myocardial trabecular extensions by E9

Genotype
MGI:4430085

cn2

• Allelic Composition: Efnb2^tm2And/Efnb2^tm2And; Tg(CAG-cre/Esr1*)1Egwa/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * DBA/2

mortality/aging

postnatal lethality, complete penetrance ( J:157054 )

• some pups become frail and subsequently die with tamoxifen treatment on first two days postnatal

growth/size/body

postnatal growth retardation ( J:157054 )

• seen with tamoxifen treatment on first two days postnatal

cardiovascular system

abnormal angiogenesis ( J:157054 )

• with tamoxifen treatment, vascular morphology in the dermis is severely affected, with dilatation of the vascular lumen

integument

integument phenotype ( J:157054 )

N • with tamoxifen treatment, infiltration of leukocytes is comparable to untreated controls and is not cause of hypercornification

retarded hair growth ( J:157054 )

• seen at P9 with tamoxifen treatment on first two days postnatal

thin hypodermis ( J:157054 )

• seen at P9 seen with tamoxifen treatment on first two days postnatal

small hair follicles ( J:157054 )

• seen with tamoxifen treatment on first two days postnatal, pups have shorter hair follicles

hyperkeratosis ( J:157054 )

• hypercornification of skin is observed seen at P9 with tamoxifen treatment on first two days postnatal

• with tamoxifen treatment, no difference is detected at P4

thick epidermis ( J:157054 )

• seen at P9 with tamoxifen treatment on first two days postnatal

flaky skin ( J:157054 )

• observed initially by P5 and peaking between 1 and 2 weeks of age with tamoxifen treatment on first two days postnatal

abnormal skin physiology ( J:157054 )

• enhanced proliferation of epidermal progenitor cells is detected with tamoxifen treatment at P1-2